![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, July 28, 2016 12:57:18 AM
Frost likely didn't like the price reaction to BSR attack. So he reduced exposure slightly. It is also conceivable that his Philanthropic Foundation might have a near-term fund need. So he couldn't afford to subject all of it to near-term volatility, thus why he reduced ~1/4 in that part of holding which was also the bulk of the reduction.
Furthermore, he likely needs money to continue his purchase of OPK shares. Lakewood Capital pointed out back in 2013 that Frost knew that he needs to keep on purchasing OPK shares. Otherwise, the stock could collapse. He's been out there buying OPK shares in the open market for years. And his stake in OPK has now grown to over $1.8B worth. So he just can't afford to stop. One might reasonably suspect that he liquidated his entire Pershing Gold holding in May at least partly because he wants to fund his ongoing OPK share purchases.
The notion that Frost "knows something" when he buys or sells shares is a myth. That's according to Lakewood, who pointed out that despite Frost's continuing purchases of OPK shares, the company's endeavors continued to fail miserably. Dr. Frost's share purchase is merely a reflection of his own belief that he himself is capable of making OPK a great success in the end.
Now that's the company he runs himself. Regarding CDXC, he is not even a board member. He is just a major shareholder (still 10+% after the reduction). So no, he does not know something you don't about CDXC. Oh, that's assuming you have done your own research on CDXC.
It's now obviously that Dr. Frost was unlikely part of the early June $5.25 million registered direct offering. That commitment most likely came from Honig/Brauser, if I have to guess.
Recent CDXC News
- ChromaDex to Join Russell 2000® Index • Business Wire • 07/01/2024 12:32:00 PM
- Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) • Business Wire • 06/24/2024 12:32:00 PM
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) • Business Wire • 06/13/2024 12:32:00 PM
- ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) • Business Wire • 06/07/2024 12:34:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 • Business Wire • 06/04/2024 12:32:00 PM
- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • Business Wire • 05/23/2024 12:34:00 PM
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award • Business Wire • 05/22/2024 12:32:00 PM
- ChromaDex Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/08/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:02:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:05 PM
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement • Business Wire • 04/30/2024 12:32:00 PM
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® • Business Wire • 04/25/2024 12:34:00 PM
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 • Business Wire • 04/24/2024 12:34:00 PM
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market • Business Wire • 04/23/2024 12:32:00 PM
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program • Business Wire • 03/26/2024 12:32:00 PM
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 03/06/2024 09:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 02:00:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:59:47 AM
- ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 • Business Wire • 02/21/2024 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 • Business Wire • 02/05/2024 01:32:00 PM
- ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference • Business Wire • 01/26/2024 09:08:00 PM
- ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® • Business Wire • 12/20/2023 02:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:16 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM